- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05132296
Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer
Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer Multicenter Pilot Trial
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. Assess the feasibility of delivering a mobile, standardized, comprehensive lifestyle program in women with breast cancer (BCa).
SECONDARY OBJECTIVES:
I. Determine whether the comprehensive lifestyle intervention program (CLIP) group has reduction in body mass index (BMI) and percent body fat and weight over time.
II. Determine whether the CLIP group has improved outcomes in anthropometric measures, dietary patterns, and fitness measures and patient-reported outcomes including quality of life (QOL), fatigue, sleep disturbances, mental health, social support, and mindfulness.
OUTLINE: Patients are randomized into 1 of 2 groups.
GROUP I: Patients undergo 60 minute sessions of nutrition education for 12 weeks and behavioral intervention 26 weeks. Patients receive FitBit and undergo physical activity for 30-60 minutes 5 days a week (aerobic activity) and 2 days a week (resistance training).
GROUP II: Patients have access to all usual care supportive services.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women with stage I-III BCa scheduled to undergo radiation therapy (RT) or within the first 12 months of having completed primary treatment (they do not need to have undergone RT)
- Underwent chemotherapy and surgery
- Able to read, write, and speak English
- BMI of 25 or higher
- 18 years of age or older
- Oriented to person, place, and time
Participants must meet at least two of the following criteria related to their lifestyle at the time of diagnosis:
- Consume less than 3 servings of fruit and vegetable/day
- Engage in less than 75 minutes of moderate/vigorous intensity activity per week, defined as anything that causes small increases in breathing or heart rate for a sustained amount of time (e.g., brisk walking, bicycling)
- Engage in a mind-body practice less than 4 times a month
- Access to internet connection
- Access to a tablet, laptop or computer
- Able to come to University of Texas (UT) MD Anderson or Wake Forest for blood collection
- Able to perform light physical activity. if any medical issues exist or arise that may limit performing physical activity, a medical release will be required
Exclusion Criteria:
- Have not completed chemotherapy; have a recurrent BCa diagnosis; another primary cancer diagnosis within past 5 years (not including non-melanoma skin cancers)
- Any major thought disorder (e.g., schizophrenia, dementia)
- Any major communication barriers that would preclude being able to complete the intervention (e.g., visually or hearing impaired)
- Poorly or uncontrolled diabetes in the opinion of the physician(s)
- Extreme mobility issues (e.g., unable to get in and out of a chair unassisted)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: GROUP I (CLIP)
Patients undergo 60 minute sessions of nutrition education for 12 weeks and behavioral intervention 26 weeks.
Patients receive FitBit and undergo physical activity for 30-60 minutes 5 days a week (aerobic activity) and 2 days a week (resistance training).
|
Ancillary studies
Undergo behavioral counseling
Other Names:
Receive FitBit
Receive nutrition education
Undergo physical activity
|
|
Active Comparator: GROUP II (usual care)
Patients have access to all usual care supportive services.
|
Ancillary studies
Receive usual care supportive services
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess the feasibility of delivering a mobile, standardized, comprehensive lifestyle program in women with BCa.
Time Frame: up to 9 months after study baseline
|
The feasibility criteria will include consent rate (how many patients are consented in a period of time), adherence rate ( how many patients adhere to the program and finish it), and study retention rate ( how many patients that are consented stay with the program until the end/ low number of participants withdrawing from the study after consent).
|
up to 9 months after study baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lorenzo Cohen, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Skin Diseases
- Breast Diseases
- Skin and Connective Tissue Diseases
- Breast Neoplasms
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Motor Activity
- Movement
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Quality Indicators, Health Care
- Psychotherapy
- Behavioral Disciplines and Activities
- Epidemiologic Measurements
- Guidelines as Topic
- Quality Assurance, Health Care
- Exercise
- Standard of Care
- Practice Guidelines as Topic
- Nutrition Assessment
- Behavior Therapy
Other Study ID Numbers
- 2020-1190 (Other Identifier: M D Anderson Cancer Center)
- UG1CA189824 (U.S. NIH Grant/Contract)
- NCI-2021-08961 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Carcinoma
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in SituUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Cianna Medical, Inc.TerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma and other conditionsUnited States
-
Case Comprehensive Cancer CenterWithdrawnStage I Breast Cancer | HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Lobular Breast Carcinoma | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast CarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Canadian Cancer Trials GroupActive, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Lobular Breast Carcinoma | Ductal Breast Carcinoma | Tubular Breast Carcinoma | Medullary Breast CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Triple-Negative Breast Carcinoma | HER2-Negative Breast Carcinoma | Bilateral Breast Carcinoma | Localized Breast CarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Pfizer; University of California, San Francisco and other collaboratorsCompletedPostmenopausal | Ductal Breast Carcinoma In SituUnited States
-
University of Texas at AustinWashington University School of Medicine; Ohio State UniversityCompletedStage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Ductal Carcinoma in Situ | Lobular Breast Carcinoma | Stage III Breast Cancer | Ductal Breast CarcinomaUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
Gulseren Demir KarakilicCompletedMusculoskeletal Diseases | Chronic PainTurkey (Türkiye)
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden